Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | ICMT | O60725 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12792322 | 1.00 | CASP2 (0.44) | CASP2NAAAHPGDDNM1DRD2 | |
| SCHEMBL12791765 | 1.00 | CASP2 (0.44) | CASP2NAAAHPGDDNM1DRD2 | |
| SCHEMBL18871254 | 0.88 | CASP2 (0.51) | CASP2NAAAHPGDDNM1FAAH | |
| SCHEMBL17952398 | 0.88 | CASP2 (0.51) | CASP2NAAAHPGDDNM1FAAH | |
| SCHEMBL7977295 | 0.84 | FAAH (0.52) | CASP2NAAAHPGDDNM1FAAH | |
| SCHEMBL7971173 | 0.84 | FAAH (0.52) | CASP2NAAAHPGDDNM1FAAH | |
| SCHEMBL16330407 | 0.83 | HDAC3 (0.36) | — | |
| SCHEMBL17817370 | 0.83 | FAAH (0.50) | DNM1FAAHMEN1MAPTKMT2A | |
| SCHEMBL7961176 | 0.83 | FAAH (0.50) | CASP2HPGDDNM1FAAHMEN1 | |
| SCHEMBL10820667 | 0.82 | HRH3 (0.41) | FAAHICMTALBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009657-A1 | AMINE-CONTAINING LIPIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-01-14 | — | — | US | disclosed |
| US-9006487-B2 | Amine-containing lipids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, SGMS1, APOB | CASP2 1497/4885NAAA 625/4885HPGD 2520/4885 |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | PHOSPHO1, CHMP4B, SGMS1 | CASP2 3638/4885NAAA 78/4885HPGD 2400/4885 |
| US-20160009657-A1 | AMINE-CONTAINING LIPIDS AND USES THEREOF | PHOSPHO1, CHMP4B, SGMS1 | CASP2 3638/4885NAAA 78/4885HPGD 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.